So here are some takeaways on the longevity of the obesity platform: Even without GLP-1 craze they grew the business (profitably?) to a $100M run-rate in 7 months with oral weight loss medications alone We will see a flood of new GLP-1 medications enter the market and the situation will move quickly and be fluid including the introduction of oral compounds that may lead to other use-cases for Hims There is some sort of precedent that compounding certain elements like end-dosage or side effect mitigation is considered clinically necessary and therefore defensible Hims & Hers will also offer brand-name GLP-1s on platform, maybe alluding to expectations of reduction in out of pocket cost over time, or an increase in supply My unsolicited thoughts for Hims would be to take advantage of this huge surge in cash and invest it into the sustainable, growing parts of the business
When patients stayed on treatment for the full duration, that number climbed to 16.6%, essentially matching the weight loss performance of injectable WEGOVY 2.4 mg
Moreover, our data provide evidence of an unappreciated pathway for KG to promote carnitine synthesis that supports histone acetylation in addition to its known roles in demethylation
Confirm current details directly on the official website before enrolling
These revolutionary treatments, known for their effectiveness in aiding weight loss and improving overall health, have redefined how we approach obesity and metabolic health
Our focus is on making weight loss solutions both effective and accessible
